遗传性出血性毛细血管扩张症1例并文献复习
作者:

Hereditary hemorrhagic telangiectasia: a case report and literature review
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • | |
    摘要:

    目的 探讨遗传性出血性毛细血管扩张症(HHT)的临床特点及诊疗方法,以便对其进行早期诊断,为临床工作提供帮助。方法 回顾性分析1例因“反复鼻出血6年”在广东医科大学附属医院耳鼻咽喉头颈外科就诊患者的临床资料及家系患病情况。应用全外显子组测序技术对先证者进行疑似致病基因筛选,应用Sanger测序对先证者及其父亲进行家系验证。结果 先证者及其父亲均有反复鼻出血、鼻腔黏膜毛细血管扩张表现,先证者弟弟具有脑血管畸形病史。全外显子测序显示先证者携带ENG基因c.1361T>C(p.Leu454Pro)杂合突变,Sanger测序显示其父亲携带相同的变异。结论 ENG基因c.1361T>C(p.Leu454Pro)杂合突变为ENG基因中新突变位点,目前为止,gnomAD数据库、clinvar数据库、ESP数据库、千人数据库、EXAC数据库均未见报道,扩展了HHT致病基因ENG的基因变异谱。

    Abstract:

    Objective To explore the clinical features, diagnosis and treatment of hereditary hemorrhagic telangiectasia (HHT),it will provide help for the early diagnosis of HHT in clinical work. Methods It was retrospectively analyzed for the clinical data and family status of a patient admitted to the Departmant of Otorhinolaryngology Head and Neck Surgery of the Affiliated Hospital of Guangdong Medical University due to “recurrent nasal bleeding for 6 years”. The whole exome sequencing (WES) was used to screen suspected pathogenic genes in probands, and Sanger sequencing was used to verify the pedigree of the probands and their family members. Results Both the proband and his father had recurrent epistaxis and mucous telangiectasia. The younger brother of the proband had a history of cerebrovascular malformation. WES revealed that the proband carried a heterozygous mutation of ENG gene C.1361T>C(p.Leu454Pro), while Sanger sequencing showed that his father carried the same mutation. Conclusion The heterozygous mutation of ENG gene C.1361T>C (p.Leu454Pro) is a novel mutation site in ENG gene, which has not been reported in gnomAD database, clinvar database, ESP database,Thousand Genomes Project database and EXAC database. The novel mutation site of ENG gene extended the gene variation spectrum of HHT pathogenic genes.

    网友评论
    网友评论
    分享到微博
    发 布
    参考文献
    [1] Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)[J]. Am J Med Genet,2000,91(1):66-67.
    [2] Floria M, Nǎfureanu ED, Iov DE, et al. Hereditary Hemorrhagic Telangiectasia and Arterio-Venous Malformations-From Diagnosis to Therapeutic Challenges[J]. J Clin Med, 2022, 11(9): 26-34.
    [3] McDonald J, Wooderchak-Donahue W, VanSant Webb C,et al.Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era[J]. Front Genet, 2015,6:1.
    [4] Robert F, Desroches-Castan A, Bailly S, et al.Future treatments for hereditary hemorrhagic telangiectasia[J]. Orphanet J Rare Dis,2020,15(1):1281-1284.
    [5] 赵亚丽, 王向东, 张媛, 等. 遗传性出血性毛细血管扩张症病例表型和基因型分析[J]. 国际耳鼻咽喉头颈外科杂志, 2022, 46(2): 68-72.
    [6] Hernandez F,Huether R,Carter L,et al.Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia[J]. Hum Genome Var,2015, 2: 15040.
    [7] Pagella F, Colombo A, Matti E, et al. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients[J]. Am J Rhinol Allergy, 2009,23(1):52-58.
    [8] Faughnan ME, Mager JJ, Hetts SW, et al.Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia[J]. Ann Intern Med, 2020,173(12):989-1001.
    [9] Albinana V,Giménez-Gallego G,García-Mato A,et al. Topically applied etamsylate: A new orphan drug for hht-derived epistaxis (antiangiogenesis through fgf pathway inhibition)[J]. TH Open,2019,3(3):e230-e243.
    [10] Buscarini E,Botella LM,Geisthoff U,et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia[J]. Orphanet J Rare Dis,2019,14(1):28.
    [11] Al-Samkari H, Kasthuri RS,Parambil JG,et al. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: The InHIBIT-bleed study[J]. Haematologica, 2021, 106(8):2161-2169
    [12] Fang J, Chen X, Zhu B, et al. Thalidomide for epistaxis in patients with hereditary hemorrhagic telangiectasia: A preliminary study[J]. Otolaryngol Head Neck Surg, 2017, 157(2):217-221.
    [13] Zarrabeitia R,Ojeda-Fernandez L,Recio L, et al. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia[J]. Thromb Haemost,2016,115(6):1167- 1177.
    [14] Mei-Zahav M,Gendler Y,Bruckheimer E,et al. Topical propranolol improves epistaxis control in hereditary hemorrhagic telangiectasia (hht):A randomized double-blind placebo-controlled trial[J]. J Clin Med,2020,9(10):3130.
    [15] 孙凤,高明洁,雍彦礼. 补肾健脾法治疗遗传性出血性毛细血管扩张症体会[J/OL]. 世界最新医学信息文摘:电子版,2014,8 (8):136-141.
    [16] 范愈燕,王向东,锡林,等. 玉女煎加味治疗遗传性出血性毛细血管扩张症的疗效观察[J]. 中国耳鼻咽喉头颈外科,2015,22(3): 128-131.
    [17] Tortora A,Riccioni ME,Gaetani E,et al. A Rendu-Osler-Weber Disease: A gastroenterologist’s perspective[J]. Orphanet J Rare Dis, 2019, 14: 130.
    [18] Faughnan ME, Palda VA, Garcia-Tsao G,et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia[J]. J Med Genet, 2011,48(2):73-87.
    引证文献
引用本文

宁宁,姚俊,刘磊峰,许梅,邱海涛,江枫.遗传性出血性毛细血管扩张症1例并文献复习[J].中国耳鼻咽喉颅底外科杂志,2024,30(5):103-106

复制
分享
文章指标
  • 点击次数:45
  • 下载次数: 93
历史
  • 收稿日期:2023-11-20
  • 在线发布日期: 2024-11-05
温馨提示

本刊唯一投稿网址:www.xyosbs.com
唯一办公邮箱:xyent@126.com
编辑部联系电话:0731-84327210,84327469
本刊从未委托任何单位、个人及其他网站代理征稿及办理其他业务联系,谨防上当受骗!

关闭